+Compare
BNTX
Stock ticker:
NASDAQ
AS OF
Oct 6 closing price
Price
$137.53
Change
+$0.34 (+0.25%)
Capitalization
32.47B

BNTX Price Prediction, BioNTech SE American Depositary Share AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

GET INTRADAY SIGNALS
BNTX Trading results, last 6 months
AI Robots NameP/L
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Oct 06, 2022

Momentum Indicator for BNTX turns positive, indicating new upward trend

BNTX saw its Momentum Indicator move above the 0 level on October 03, 2022. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 47 similar instances where the indicator turned positive. In 43 of the 47 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for BNTX just turned positive on September 30, 2022. Looking at past instances where BNTX's MACD turned positive, the stock continued to rise in of 24 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BNTX advanced for three days, in of 195 cases, the price rose further within the following month. The odds of a continued upward trend are .

BNTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for BNTX entered a downward trend on September 22, 2022. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.008) is normal, around the industry mean (26.140). P/E Ratio (3.082) is within average values for comparable stocks, (91.441). Projected Growth (PEG Ratio) (0.046) is also within normal values, averaging (3.845). Dividend Yield (0.013) settles around the average of (0.026) among similar stocks. P/S Ratio (1.709) is also within normal values, averaging (292.549).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BNTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published Earnings

BNTX is expected to report earnings to fall 43.88% to $3.62 per share on November 07

BioNTech SE American Depositary Share BNTX Stock Earnings Reports
Q3'22
Est.
$3.62
Q2'22
Missed
by $0.63
Q1'22
Beat
by $5.08
Q4'21
Beat
by $4.74
Q3'21
Beat
by $1.81
The last earnings report on August 08 showed earnings per share of $6.45, missing the estimate of $7.08. With 300.87K shares outstanding, the current market capitalization sits at 32.47B.
AI
A.I.Advisor
published Dividends

BNTX paid dividends on June 17, 2022

BioNTech SE American Depositary Share BNTX Stock Dividends
А dividend of $4.22 per share was paid with a record date of June 17, 2022, and an ex-dividend date of June 02, 2022. Read more...
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Global Blood Therapeutics (NASDAQ:GBT), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.64B. The market cap for tickers in the group ranges from 160 to 222.71B. NONOF holds the highest valuation in this group at 222.71B. The lowest valued company is CDXI at 160.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 4%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was -15%. LOGC experienced the highest price growth at 613%, while NSHSF experienced the biggest fall at -76%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -38%. For the same stocks of the Industry, the average monthly volume growth was -67% and the average quarterly volume growth was -89%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 70
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: -6 (-100 ... +100)
AI
View a ticker or compare two or three
BNTX
Buy/Sell Ratings
 
 
Technical Analysis# Of IndicatorsAvg. Odds
   
   
 
AI
A.I. Advisor
published General Information

General Information

a company, which focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
An der Goldgrube 12
Phone
+49 613190840
Employees
3082
Web
https://www.biontech.de
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MERC13.650.16
+1.19%
Mercer International
YUMC49.89-0.68
-1.34%
Yum China Holdings
SEV2.50-0.04
-1.57%
Sono Group NV
WD87.47-2.11
-2.36%
Walker & Dunlop
ZCMD1.14-0.05
-4.20%
Zhongchao

BNTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BNTX has been closely correlated with MRNA. These tickers have moved in lockstep 84% of the time. This A.I.-generated data suggests there is a high statistical probability that if BNTX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BNTX
1D Price
Change %
BNTX100%
+0.25%
MRNA - BNTX
84%
Closely correlated
-0.37%
CVAC - BNTX
56%
Loosely correlated
-2.19%
VIR - BNTX
56%
Loosely correlated
-4.09%
ARCT - BNTX
51%
Loosely correlated
-0.43%
MRVI - BNTX
47%
Loosely correlated
-1.83%
More